The importance of iron in pathophysiologic conditions

Frontiers in Pharmacology

Volumn 6, Issue FEB, 2015, Pages

  Gozzelino, Raffaella ^a   Arosio, Paolo ^b  

^a INSTITUTO GULBENKIAN DE CIÊNCIA   (Portugal)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Heme iron; Iron; Iron and cardiotoxicity; Iron and genetic disorders; Iron and inflammation; Iron and neurodegeneration; Iron deficiency and anemia; Iron metabolism

Indexed keywords

BONE MORPHOGENETIC PROTEIN; HEME; HEPCIDIN; IRON;

ALZHEIMER DISEASE; ANEMIA; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL RESPIRATION; CELL SURVIVAL; DNA SYNTHESIS; HEME SYNTHESIS; HEMOCHROMATOSIS; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; INCIDENCE; IRON ABSORPTION; IRON DEFICIENCY; IRON METABOLISM; IRON TRANSPORT; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NONHUMAN; OXIDATIVE STRESS; OXYGEN TRANSPORT; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84926476209     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00026     Document Type: Article

References (21)

1. Basuli, D., Stevens, R. G., Torti, F. M., and Torti, S. V. (2014). Epidemiological associations between iron and cardiovascular disease and diabetes. Front. Pharmacol. 5:117. doi: 10.3389/fphar.2014.00117
2. Busti, F., Campostrini, N., Martinelli, N., and Girelli, D. (2014). Iron deficiency in the elderly population, revisited in the hepcidin era. Front. Pharmacol. 5:83. doi: 10.3389/fphar.2014.00083
3. Cabantchik, Z. I. (2014). Labile iron in cells and body fluids: physiology, pathology, and pharmacology. Front. Pharmacol. 5:45. doi: 10.3389/fphar.2014.00045
4. Cabantchik, Z. I., Munnich, A., Youdim, M. B., and Devos, D. (2013). Regional siderosis: a new challenge for iron chelation therapy. Front. Pharmacol. 4:167. doi: 10.3389/fphar.2013.00167
5. Chiabrando, D., Vinchi, F., Fiorito, V., Mercurio, S., and Tolosano, E. (2014). Heme in pathophysiology: a matter of scavenging, metabolism and trafficking across cell membranes. Front. Pharmacol. 5:61. doi: 10.3389/fphar.2014.00061
6. Clark, M. A., Goheen, M. M., and Cerami, C. (2014). Influence of host iron status on Plasmodium falciparum infection. Front. Pharmacol. 5:84. doi: 10.3389/fphar.2014.00084
7. Core, A. B., Canali, S., and Babitt, J. L. (2014). Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis. Front. Pharmacol. 5:104. doi: 10.3389/fphar.2014.00104
8. Gammella, E., Maccarinelli, F., Buratti, P., Recalcati, S., and Cairo, G. (2014). The role of iron in anthracycline cardiotoxicity. Front. Pharmacol. 5:25. doi: 10.3389/fphar.2014.00025
9. Korolnek, T., and Hamza, I. (2014). Like iron in the blood of the people: the requirement for heme trafficking in iron metabolism. Front. Pharmacol. 5:126. doi: 10.3389/fphar.2014.00126
10. Levi, S., and Finazzi, D. (2014). Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms. Front. Pharmacol. 5:99. doi: 10.3389/fphar.2014.00099
11. Nairz, M., Haschka, D., Demetz, E., and Weiss, G. (2014). Iron at the interface of immunity and infection. Front. Pharmacol. 5:152. doi: 10.3389/fphar.2014.00152
12. Penha-Goncalves, C., Gozzelino, R., and de Moraes, L. V. (2014). Iron overload in Plasmodium berghei-infected placenta as a pathogenesis mechanism of fetal death. Front. Pharmacol. 5:155. doi: 10.3389/fphar.2014.00155
13. Poli, M., Asperti, M., Ruzzenenti, P., Regoni, M., and Arosio, P. (2014). Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front. Pharmacol. 5:86. doi: 10.3389/fphar.2014.00086
14. Silvestri, L., Nai, A., Pagani, A., and Camaschella, C. (2014). The extrahepatic role of TFR2 in iron homeostasis. Front. Pharmacol. 5:93. doi: 10.3389/fphar.2014.00093
15. Spottiswoode, N., Duffy, P. E., and Drakesmith, H. (2014). Iron, anemia and hepcidin in malaria. Front. Pharmacol. 5:125. doi: 10.3389/fphar.2014.00125
16. Urrutia, P. J., Mena, N. P., and Nunez, M. T. (2014). The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. Front. Pharmacol. 5:38. doi: 10.3389/fphar.2014.00038
17. Vinchi, F., Muckenthaler, M. U., Da Silva, M. C., Balla, G., Balla, J., and Jeney, V. (2014). Atherogenesis and iron: from epidemiology to cellular level. Front. Pharmacol. 5:94. doi: 10.3389/fphar.2014.00094
18. Vujic, M. (2014). Molecular basis of HFE-hemochromatosis. Front. Pharmacol. 5:42. doi: 10.3389/fphar.2014.00042
19. Wang, C. Y., Meynard, D., and Lin, H. Y. (2014). The role of TMPRSS6/matriptase-2 in iron regulation and anemia. Front. Pharmacol. 5:114. doi: 10.3389/fphar.2014.00114
20. Wong, B. X., and Duce, J. A. (2014). The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders. Front. Pharmacol. 5:81. doi: 10.3389/fphar.2014.00081
21. Zhang, D. L., Ghosh, M. C., and Rouault, T. A. (2014). The physiological functions of iron regulatory proteins in iron homeostasis - an update. Front. Pharmacol. 5:124. doi: 10.3389/fphar.2014.00124